Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC.

Vasko KramerRené FernándezWencke LehnertLuis David Jiménez-FrancoCristian Soza-RiedElisabeth EppardMatias CeballosMarian MeckelMartina BenešováChristoph A UmbrichtAndreas KlugeRoger SchibliKonstantin ZhernosekovHoracio AmaralCristina Müller

Published in: European journal of nuclear medicine and molecular imaging (2020)

Our data demonstrated that the concept of albumin-binding PSMA-radioligands is feasible and leads to increased tumor doses. After further optimization of the ligand design, the therapeutic outcomes may be improved for patients with prostate cancer.

Keyphrases

pet imaging
pet ct
prostate cancer
radical prostatectomy
binding protein
electronic health record
positron emission tomography
big data
computed tomography
type diabetes
adipose tissue
deep learning
skeletal muscle
artificial intelligence
weight loss